Abstract |
The clinical benefit of currently available tar blend shampoos for the treatment of scalp psoriasis is restricted due to their limited efficacy, low cosmetic appeal and potential for carcinogenicity. This 4-week multicentre, randomized, parallel-group, investigator-masked study included 162 subjects and aimed to compare the efficacy, safety and cosmetic acceptability of clobetasol propionate 0.05% shampoo versus a currently marketed tar blend 1% shampoo in subjects with moderate to severe scalp psoriasis. Clobetasol propionate shampoo was superior to tar blend shampoo with respect to all efficacy variables tested (p<0.001): Total and Global Severity Score; erythema; plaque thickening; desquamation; pruritus; total scalp area involved; and the subject's global assessment of clinical improvement. Both treatments were safe and well-tolerated. Furthermore, more subjects indicated that clobetasol propionate shampoo was more cosmetically acceptable than tar blend shampoo. Clobetasol propionate 0.05% shampoo is a good alternative to tar blend shampoo in the treatment of moderate to severe scalp psoriasis.
|
Authors | Christopher E M Griffiths, Andrew Y Finlay, Colin J Fleming, Jonathan N W N Barker, Fabienne Mizzi, Stéphanie Arsonnaud |
Journal | The Journal of dermatological treatment
(J Dermatolog Treat)
Vol. 17
Issue 2
Pg. 90-5
( 2006)
ISSN: 0954-6634 [Print] England |
PMID | 16766333
(Publication Type: Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Hair Preparations
- Keratolytic Agents
- Tars
- Clobetasol
|
Topics |
- Administration, Cutaneous
- Clobetasol
(administration & dosage, analogs & derivatives)
- Double-Blind Method
- Female
- Hair Preparations
- Humans
- Keratolytic Agents
(administration & dosage)
- Male
- Middle Aged
- Psoriasis
(drug therapy, pathology)
- Scalp Dermatoses
(drug therapy, pathology)
- Severity of Illness Index
- Tars
- Treatment Outcome
|